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Abstract
Background: The Amplatzer Amulet (St. Jude Medical, Minneapolis, MN, USA) is a second gen-
eration Amplatzer device for left atrial appendage (LAA) occlusion (LAAO) for stroke prophylaxis in 
patients with atrial fibrillation. This research sought to assess the clinical performance of the Amplatzer 
Amulet device and in follow up for 12 months.
Methods: In this single-center registry patients with atrial fibrillation and contraindication to oral 
anticoagulation underwent LAAO with the Amplatzer Amulet device. Follow-up was performed before 
discharge, by transesophageal echocardiography (TEE) after 6 weeks and telephone interview after 3, 
6 and 12 months. 
Results: Between October 2014 and August 2015 50 patients (76.1 ± 8.3 years; 30 male) were en-
rolled. Procedural success was achieved in 49 (98%) patients. Major periprocedural adverse events were 
observed in 4 (8%) of patients: 1 device embolization, 2 pericardial effusions requiring pericardiocente-
sis and 1 prolonged hospital stay due to retropharyngeal hematoma from the TEE probe. Follow-up TEE 
was available in 38 of 50 patients showing complete LAA sealing in all. 2 device-related thrombi were 
also documented. At 12-month follow-up 7 patients had died unrelated to the device. Ischemic stroke 
occurred in 3 patients. According to neurological examination two were classified as microangiopathic 
and not cardio-embolic. The other one could not be classified. Bleeding complications (5 minor, 3 major) 
were documented in 8 patients.
Conclusions: Although minimizing procedure-related complications remains challenging, LAAO with 
the Amplatzer Amulet device showed high procedural success and excellent LAA sealing. (Cardiol J  
2017; 24, 2: 131–138)
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Introduction
Thrombus in the left atrial appendage (LAA) 
is the principle cause of cardio-embolic events 
such as stroke in patients with non-valvular 
atrial fibrillation (AF) [1]. The randomized Pro-
tect AF and PREVAIL trials showed that LAA 
occlusion (LAAO) with the Watchman device 
(Atritech, Boston Scientific, Natick, MA, USA) 
is an alternative for oral anticoagulation (OAC) 
for stroke prophylaxis in patients with AF [2, 3]. 
The first generation Amplatzer Cardiac Plug 
(ACP, St. Jude Medical, Minneapolis, MN, USA) 
was first introduced in 2008. It consists of two 
major components: a distal lobe that secures the 
device in the LAA body and a proximal disc that 
covers the ostium [4]. A multicentre registry of 
1,047 patients demonstrated high procedural suc-
cess (97.3%) and a low annual rate of systemic 
thrombembolism (2.3%) [5].
The Amplatzer Amulet (St. Jude Medical, 
Minneapolis, MN, USA) is the second generation 
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Amplatzer device that has been developed to fa-
cilitate implantation and to reduce device-related 
complications like embolisation or leak [6].
First series of LAAO with the Amplatzer 
Amulet showed similar procedural and short-term 
clinical outcomes compared with the ACP [7–10]. 
In the series of Abualsaud et al. [11] with 50 pa-
tients the Amulet was associated with a significant 
reduction in residual leaks at follow-up.
In this single-centre registry it was sought to 
assess the clinical performance of the Amplatzer 
Amulet device at 12-months follow-up.
Methods
All consecutive patients who underwent LAAO 
with the Amplatzer Amulet at the Department of 
Cardiology, Klinikum Coburg, Germany between 
October 2014 and August 2015 were retrospec-
tively enrolled in the study. Patient characteristics, 
procedural and echocardiographic data as well as 
adverse events were collected in a database. Eli-
gibility criteria for LAAO were AF (paroxysmal, 
persistent or permanent) with indication for OAC 
(CHA2DS2-VASc Score ≥ 1) and contraindication for 
OAC or the patient’s explicit request for LAAO as 
alternative to OAC. Exclusion criteria were throm-
bus in the LAA, planned cardiac surgery, previous 
closure of the interatrial septum by surgery or 
device implantation, active endocarditis or other 
serious infections. All patients provided written 
informed consent before the procedure. This reg-
istry was initiated by the investigators. There was 
no external funding. 
Amplatzer Amulet
The Amplatzer Amulet has undergone several 
changes in relation to the ACP. The self-expanding 
device is made of braided nitinol mesh. It consists 
of a lobe and a disc connected by a central waist. 
The distal lobe anchors through stabilizing wires 
within the so called landing zone of the LAA. The 
proximal disc covers the LAA orifice (Fig. 1).
Eight sizes (smaller devices: 16, 18, 20, 22 mm, 
larger devices: 25, 28, 31, 34 mm) accommodate 
varying LAA anatomies with landing zone diame-
ters from 13 mm to 31 mm. An increased lobe 
length (smaller devices: 7.5 mm, larger devices: 
10 mm) and a higher number of stabilizing wires in 
larger devices increase the overall stability.
The disc diameter (smaller devices: lobe + 
+ 6 mm, larger devices: lobe + 7 mm) has been 
increased for better coverage of the LAA orifice. 
The end screw on the disc has been recessed to 
avoid thrombus formation in the LAA. The waist 
length (smaller devices: 5.5 mm, larger devices: 
8 mm) between lobe and disc has been increased for 
more flexible placement of the lobe within the LAA. 
The device is pre-loaded in a loader and pre-
attached to the delivery cable. This setup facilitates 
loading into the delivery sheath and is intended to 
minimize air embolism. The device is delivered to 
the LAA through a TorqVue 45° × 45° double-bend 
sheath (sizes: 16–25 mm: 12 or 14 French with 
adapter, sizes 25–34 mm: 14 French) [12]. 
Procedure 
Transesophageal echocardiography (TEE) 
(Vivid E9 and Vivid S6, GE Healthcare, Milwaukee, 
Figure 1. Indications for left atrial appendage occlusion; INR — international normalized ratio; OAC — oral antico-
agulation.
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USA) was performed before and during the proce-
dure to rule out LAA thrombus and to determine 
LAA size with measurement of the orifice, landing 
zone and depth from different angles (0°, 45°, 90°, 
130° and 180°). One operator was expert (> 1000 
procedures), 1 operator was experienced (> 50 pro-
cedures) and 1 operator was new to the procedure 
(< 5 procedures). All procedures were performed 
with local anesthesia and under conscious sedation. 
After venous access and TEE guided transseptal 
puncture heparin was administered (activated clot-
ting time > 250 s). All procedures were performed 
via transseptal puncture in inferoposterior loca-
tion to achieve perpendicular sheath angulation 
with respect to the long axis of the LAA. Since 
a patent foramen ovale (PFO) is usually located at 
a more anterior and superior position, in case of 
a PFO, care was taken not to puncture through the 
PFO. LAA angiogram was performed with a pigtail 
catheter in right anterior oblique caudal and cranial 
projections. For choosing the appropriate Amulet 
device both angiographic and echocardiographic 
measurements were taken into account oversiz-
ing the device from 3 mm to 5 mm with respect 
to the largest measured landing zone. The device 
was advanced on the delivery cable through the 
delivery sheath and positioned into the LAA. Tug 
test was performed under fluoroscopy by pulling 
and pushing the delivery cable. To intensify this 
security test in challenging LAA anatomies (shal-
low LAA with big orifice) the continuous (> 10 s) 
tug test was performed. During this maneuver the 
delivery sheath is retracted to a stable, but relaxed 
position within the LA without any rotation tension 
until the tip of the sheath is significantly separated 
from the LAA orifice. Then the delivery cable is 
gently, steadily, and continuously pulled back until 
the disc of the Amulet device is separated from the 
LAA orifice and forms the shape of a rugby-ball. 
Because the stabilizing wires of the Amulet device 
are located at the distal end of the Amulet lobe, 
a slight separation between the distal and proximal 
cage of the Amulet lobe during the continuous tug 
indicates that the stabilizing wires are trapped in 
the LAA trabeculi.
Echocardiographic and angiographic criteria 
for correct deployment were compression of the 
lobe, a perpendicular axis of lobe and LAA neck, the 
lobe positioned two thirds distal to the circumflex 
artery, separation between lobe and disc, a concave 
shape of the disc. Coverage of the orifice and re-
sidual leaks were evaluated by echocardiography 
and injecting contrast media through the delivery 
sheath. Furthermore, echocardiography evalu-
ated impingement of the mitral valve or left upper 
pulmonary vein and the presence of pericardial 
effusion. If necessary, the device was repositioned 
or a different sized device was selected. At last the 
Amulet device was released. 
Follow-up
After the procedure patients received dual 
antiplatelet therapy with clopidogrel for 3 months 
and aspirin for at least 6 months. 
Follow-up was performed in hospital by clinical 
examination and transthoracic echocardiography to 
rule out device embolisation and pericardial effusion.
Transesophageal echocardiography was per-
formed after 6 weeks to control position and en-
dothelialization of the device, detect residual leaks, 
and to observe thrombus formation or infectious 
endocarditis. 
Follow-up was done by review of all subse-
quent clinical records and structured telephone 
interviews after 3, 6 and 12 months. 
Definitions
Procedural success was defined as successful 
implantation of the Amplatzer Amulet. 
Periprocedural device- or procedure-related 
major adverse events included immediate proce-
dural mortality (< 72 h after the index procedure), 
stroke/transient ischemic attack (TIA), device 
embolization, clinically relevant cardiac tamponade 
or pericardial effusion, fatal or major bleeding, 
myocardial infarction, systemic embolism, peri-
carditis and other relevant complications leading 
to prolonged hospital stay. 
Adverse events at follow-up included cardio-
vascular and non-cardiovascular mortality, stroke/ 
/TIA and bleeding. 
According to the definition of the Bleeding 
Academic Research Consortium (BARC), [13] 
bleeding was defined as fatal (type 5) or major 
with hemoglobin drop of > 3 g/dL, requirement 
of packed red blood cell transfusions or intracra-
nial hemorrhage (type 3a-c). Minor bleeding was 
defined as not actionable (type 1) or actionable 
(type 2) requiring medical intervention, leading to 
prompt evaluation or hospitalization but not meet-
ing the criteria of major bleeding. 
Complete LAA sealing was defined as absence 
of flow or absence of residual peridevice flow > 5 mm 
assessed by color Doppler.
Statistical analysis
Categorical variables are expressed as fre-
quencies and percentages. Continuous data are 
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reported as means and standard deviation. Descrip-
tive statistical analysis was performed with SPSS 
17.0 (SPSS Inc., Chicago, Illinois, USA).
Results
Baseline characteristics
Between 01/10/2014 and 24/08/2015 a total 
of 50 patients (76.1 ± 8.3 years; 30 male) were 
enrolled. Twenty six (52%) patients had permanent 
AF. The mean CHA2DS2-VASc score was 5.2 ± 1.8 
and the mean HAS-BLED score was 3.5 ± 0.9. 
Baseline patient characteristics are summa-
rized in Table 1. Indications for LAAO are shown 
in Figure 1.
Procedural data
Procedural data are summarized in Table 2. 
Procedural success was achieved in 49/50 (98%) 
patients. In 1 patient device embolization occurred 
on the day of the procedure. 
Periprocedural major adverse events
Periprocedural major adverse events were 
observed in 4 (8%) patients. One device emboli-
zation occurred on the day of the procedure and 
required cardiac surgery. The procedure had been 
performed by the least experienced operator (< 5 
interventions). Retrospective analysis of fluoros-
copy revealed peridevice leak post-implantation 
(Fig. 2, 1A–C). At 6-month follow-up the patient 
reported full recovery.
One cardiac tamponade was drained immedi-
ately. One pericardial effusion required pericardio-
centesis at day 22 after the procedure. Whether 
cardiac tamponade or pericardial effusion were 
procedure or device-related is unknown.
One patient experienced prolonged hospital 
stay (33 days) due to retropharyngeal hematoma 
from the TEE probe necessitating mechanical 
ventilation. 
Five access site complications (10%) included 
1 bleeding type 2 and 1 bleeding type 3a according 
to the BARC bleeding definition, 2 femoral artery 
pseudoaneurysms and 1 combined pseudoaneu-
rysm and bleeding type 3a. All pseudoaneurysms 
were treated with thrombin injection. Acute renal 
injury stage 1 in 1 patient was treated with intra-
venous fluids and led to prolonged hospital stay 
(6 days).
TEE follow-up
Follow-up TEE, routinely performed after 
6 weeks, was available in 38 out of 50 patients 
Table 1. Baseline characteristics (n = 50).
Age [years] 76.1 ± 8
Age ≥ 75 years 31 (62%)
Male 30 (60%)
Permanent atrial fibrillation 26 (52%)
CHA2DS2-VASc score 5.2 ± 1.8
HAS-BLED score 3.5 ± 0.9
Previous stroke/TIA 17 (34%)
Peripheral embolization 4 (8%)
Congestive heart failure 8 (16%)
Arterial hypertension 50 (100%)
Diabetes mellitus 22 (44%)
Creatinine [mmol/L] 62 ± 22
Carotid disease 12 (24%)
Coronary artery disease 35 (70%)
Categorical variables are expressed as frequencies (n) and percent-
ages (%). Continuous data are reported as means and (±) standard 
deviation; TIA — transient ischemic attack
Table 2. Procedural data (n = 50).
Procedural success 49 (98%)
Size of Amplatzer Amulet:
16 mm 1 (2%)
20 mm 1 (2%)
22 mm 11 (22%)
25 mm 20 (40%)
28 mm 11 (22%)
31 mm 2 (4%)
34 mm 4 (8%)
LAA measurements:
Opening [mm] 22 ± 5
Landing zone [mm] 21 ± 4
Depth [mm] 25 ± 7
LAA morphology:
Chicken wing 24 (48%)
Windsock 6 (12%)
Cauliflower 11 (22%)
Cactus 4 (8%)
Cone 5 (10%)
Implantation attempts:
1 38 (76%)
2 11 (22%)
3 1 (2%)
Fluoroscopy time [min] 13 ± 7
Contrast media [mL] 118 ± 56
Categorical variables are expressed as frequencies (n) and percent-
ages (%). Continuous data are reported as means and (±) standard 
deviation; LAA — left atrial appendage
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(76%). Two patients had died before TEE follow-up. 
Several patients refused TEE follow-up because of 
comorbidities and frailty. TEE showed complete 
LAA sealing in all available studies.
In 1 patient device-related thrombus was 
found in routinely performed TEE after 6 weeks. 
It disappeared after 6 weeks of treatment with 
OAC. Retrospective analysis of fluoroscopy showed 
a cauliflower morphology of the LAA. To avoid 
embolization the device had been implanted rela-
tively deeply with the disc positioned partially in 
the neck of the LAA with the ostium of the LAA 
not fully covered. Thrombus developed in the re-
maining pouch between the LAA ostium and the 
disc (Fig. 2, 2A–C). 
The second patient was 79 years old who in 
the first instance had refused TEE control after 
6 weeks. In a later hospital stay during 12-months 
follow-up TEE detected a relatively large thrombus 
of 17 × 8 mm. Implant result on angiogram showed 
correct deployment criteria of the device with 
full coverage of the LAA ostium (Fig. 2, 3A–C). 
Therefore, the exact cause of thrombus formation 
remains unknown. However, non-adherence to 
dual antiplatelet therapy seemed possible due to 
moderate dementia (mini mental test 16 points).
Cardiac surgery was discussed by the local heart 
team. Due to frailty and comorbidities lifelong treat-
ment with OAC was considered the preferred ap-
proach. At 12-months follow-up there were no neuro-
logical complications, the patient refused control TEE.
12-month follow-up
At 12-month follow-up 7 (14%, 14 cases per 
100 patient-years) patients (83.9 ± 4.1 years) had 
died unrelated to the device or the procedure. 
Figure 2. Details of patients with device embolization and thrombus formation; 1A–C. Patient with device emboliza-
tion showing left atrial appendage (LAA) cauliflower morphology pre-implantation (1A). Deployment criteria of lobe 
and disc seem fullfilled post-implantation (1B), but angiogram reveals peridevice leak (1C); 2A–C. Patient with device 
thrombosis. X-ray post-implantation shows a remaining pouch of the LAA ostium which was not fully covered (2A). 
Transesophageal echocardiography after 6 weeks reveals a thrombus on the device (2B). After another 6 weeks of 
oral anticoagulation the thrombus has dissolved (3A); 3A–C. Patient with device thrombosis showing LAA chicken- 
-wing morphology pre-implantation (3A). X-ray post-implantation shows full coverage of the LAA ostium (3B). During 
12 months follow-up a large thrombus was detected on the device (3C); LA — left atrium.
LAA with 
cauliflower morphology Post-implantation
Peridevice leak
LAA ostium not 
fully covered 
LA LA
Thrombus
Thrombus
No thrombus
Amulet Amulet 
Amulet Post-implantation: 
LAA ostium fully covered 
 Pre-implantation: LAA with 
chicken-wing morphology
1A 1B 1C
2A 2B 2C
3A 3B 3C
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Patients aged 90, 82, 86 and 85 died as a result 
of sepsis due to urinary tract infection (2 patients), 
spontaneous bacterial peritonitis and soft tissue 
infection 2, 8, 12 months (2 patients) after the 
index procedure. 
Other causes of death in 90, 79 and 82 year 
old patients were atrioventricular-block degree III, 
decompensated chronic heart failure and acute on 
chronic kidney failure on day 11, 8 and 6 months 
after device implantation.
An autopsy was not performed in any of these 
patients nor was a TEE to rule out endocarditis. 
However, TTE, which was performed in all 
patients, showed a regular position of the Amulet 
device, and there was no suspicion of endocarditis. 
Ischemic stroke occurred in 3 (6.1%, 6 cases 
per 100 patient-years) patients. TEE in all 3 pa-
tients showed complete sealing of the LAA and 
device-related thrombus was ruled out. National 
Institutes of Health Stroke Scale (NIHSS) score 
was evaluated by an independent neurologist. 
An 83-year-old patient suffered from a disabling, 
microangiopathic stroke (NIHSS score 7). A non-
disabling, microangiopathic stroke (NIHSS score 4) 
occurred in a 76-year-old patient. A non-disabling 
stroke with paraphasia (NIHSS score 2) was docu-
mented in a 75-year-old patient. Cranial computed 
tomography scan showed a small lesion in the 
caput nuclei caudati. It could not be classified as 
microangiopathic or cardio-embolic. All 3 patients 
were treated with aspirin.
Eight bleeding complications (16%, 16 cases 
per 100 patient-years) were reported. One minor 
and 2 major bleedings occurred under dual an-
tiplatelet therapy. Major bleeding complications 
included 1 case of gastrointestinal bleeding and 
1 case of subarachnoid bleeding without neurologi-
cal deficit after a fall. One minor gastrointestinal 
bleeding and 1 minor hemoptysis occurred under 
therapy with aspirin alone. Two minor and 1 ma-
jor gastrointestinal bleedings occurred without 
antithrombotic therapy.
Discussion
This study is the first to report 12-month 
follow-ups of the Amplatzer Amulet. It showed 
high procedural success (98%) and excellent LAA 
sealing rates (100%). There was a relevant rate 
of major periprocedural complications (8%). At 
12-months follow-up no device-related complica-
tions were observed. 
Procedural success in our registry was simi-
lar to other series published using the Amplatzer 
Amulet. These series with 17 [7], 20 [8], 24 [9] 
and 50 [10] patients reported 100%, 100%, 96% 
and 94% procedural process. The Amulet obser-
vational study with 1,073 patients reported 98.8% 
implant success [14]. Since the multicentre-study 
of 1,047 patients using the first generation ACP [5] 
documented 97.3% successful implantations, these 
data suggest that procedural success of Amplatzer 
Amulet and ACP is comparable. 
Herein is documented a relevant rate of major 
periprocedural complications including 1 device 
embolization, 2 pericardial effusions requiring 
pericardiocentesis and 1 prolonged hospital stay 
due to retropharyngeal hematoma from the TEE 
probe. In this study device embolization occurred 
in a procedure performed by an operator who was 
new to the procedure (< 5 interventions). Retro-
spective analysis of fluoroscopy showed a relevant 
peridevice leak after deployment of the device 
(Fig. 2, 1A–C). Prolonged hospital stay due to ret-
ropharyngeal hematoma from the TEE probe was 
considered as a serious adverse event. Research 
indicated that other registries documented only 
major adverse events which were strictly related 
to the device and the LAAO procedure itself.
This data reflects a real-world scenario in 
a challenging patient population (mean age 76 ± 
± 8 years). Furthermore, the above described de-
vice embolization and retropharyngeal hematoma 
caused by the TEE probe reflect the learning curve 
at this center. To avoid retropharyngeal hematoma, 
this center in recent times administers heparin 
after introducing the TEE probe and, respectively, 
the procedure is even stopped if there are difficul-
ties introducing the TEE probe. 
The Protect AF trial and the continued access 
registry [15] showed a significant improvement 
of Watchman LAA closure and decreased rate of 
procedure-related complications with increased 
center and operator experience due to better 
knowledge of the LAA closure procedure and the 
device used. 
The registry of Gloekler et al. [10] with 50 
patients, who reported the first series of Amulet 
in their centers, also observed a relevant rate of 
serious procedure-related complications (12%) 
with 3 cardiac tamponades, in 1 case leading to 
death, and 3 device embolizations. 
The multicentre trial of 1,047 patients using 
the first generation ACP documented 4.97% major 
periprocedural events [5]. The ACP multicenter trial 
was based on retrospective data from 20 different 
centers including patients from first in December 
2008. Data collection began years later and on 
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operator voluntary contribution. The chance that 
a significant number of complications, possibly seri-
ous ones, could be missing and cannot be ruled out.
In the Amulet observational study with par-
ticipation at highly experienced centers the rate of 
complications could be brought down to 2.7% [14].
The TEE follow-up of this study confirms 
excellent LAA sealing rate (100%) with the 
Amplatzer Amulet. This is in line with all other 
studies.
Two device-related thrombi were detected. 
One thrombus disappeared after 6 weeks of treat-
ment with OAC, medication was then switched to 
aspirin alone. One 79-year-old patient refused TEE 
control and is still on lifelong treatment with OAC. 
In both patients there were no neurological prob-
lems. In the 79-year-old patient non-adherence to 
dual antiplatelet therapy was deemed possible due 
to moderate dementia (mini mental test 16 points). 
Implant result on angiogram showed full coverage 
of the LAA ostium (Fig. 2, 3A–C). 
In the other patient the position of the device 
could have been a possible reason for thrombus 
formation.
The device had been implanted relatively 
deeply with the disc partially positioned in the neck 
of the LAA. Since the ostium of the LAA was not 
fully covered thrombus developed in the remain-
ing pouch between the LAA ostium and the disc 
(Fig. 2, 2A–C). 
A previous study of 169 consecutive patients 
evaluated the clinical outcome according to the po-
sition of the ACP disc [16]. There was no evidence 
of relevant differences in the incidence of device-
related thrombi between patients with complete 
and incomplete disc coverage of the LAA ostium. 
However, study size and number of events were 
likely too small to detect significant differences. 
At 12-months follow-up 7 patients had died 
unrelated to the device. Those patients were con-
siderably older (83.9 ± 4.1 years) than the rest of 
the cohort (75 ± 8.2 years). Due to high CHA2DS2-
-VASc and HAS-BLED scores, elderly patients are 
likely to benefit from LAAO. However, future trials 
should examine the criteria on which to select older 
patients for LAAO. 
Three patients were documented with ischem-
ic stroke. TEE in these patients showed complete 
LAA sealing and could rule out device-related 
thrombus. Follow-up time was short and sample 
size not large enough to draw conclusions about the 
effectiveness of LAAO with the Amplatzer Amulet 
in reduction of thrombembolism. 
Eight bleeding complications were reported. 
Two major bleedings, including 1 case of suba-
rachnoid hemorrhage after a fall which occurred 
under dual antiplatelet therapy. Because of the 
design of the study, conclusions about bleeding 
risk compared between OAC and LAAO with the 
Amplatzer Amulet cannot be drawn. Still, keeping 
patients informed about increased bleeding risk 
under dual antiplatelet therapy after LAAO should 
be considered mandatory. 
Limitation of the study
The retrospective and observational character 
of the study design does not exclude selection bias, 
although consecutive patients were considered. 
This single-center experience may not reflect 
clinical practice in other catheterization labora-
tories. Since this was a non-randomized design 
comparisons cannot be made to other devices or 
treatment with OAC. The 12-month follow-up is 
of insufficient length and the sample size was not 
large enough to draw definitive conclusions about 
the risk of thrombembolism and bleeding after 
LAAO with the Amplatzer Amulet. 
Conclusions
Although minimizing procedure-related com-
plications remains challenging, LAAO with the 
Amplatzer Amulet device showed high procedural 
success and excellent LAA sealing.
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